Zosano Pharma (NASDAQ:ZSAN) was downgraded by stock analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a note issued to investors on Tuesday.
Zosano Pharma (NASDAQ ZSAN) opened at $7.68 on Tuesday. Zosano Pharma has a fifty-two week low of $3.61 and a fifty-two week high of $58.20. The company has a market capitalization of $8.80, a price-to-earnings ratio of -0.33 and a beta of 1.90.
In related news, Director Kenneth Greathouse purchased 55,000 shares of Zosano Pharma stock in a transaction dated Wednesday, December 6th. The shares were acquired at an average price of $0.61 per share, for a total transaction of $33,550.00. Following the acquisition, the director now directly owns 200,000 shares in the company, valued at $122,000. The purchase was disclosed in a filing with the SEC, which is available through this link. 2.83% of the stock is owned by insiders.
About Zosano Pharma
Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Zosano Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma and related companies with MarketBeat.com's FREE daily email newsletter.